Every quarter John Khabbaz writes to Phoenician Capital's investors about results, what we bought and sold, and why. These are the public editions of those letters, newest first.
In the third quarter of 2026 the partnership returned +0.5%, bringing its net return for the first nine months to +7.2%, against +12.8% for the S&P 500. The letter introduces Modern Dental Group, reports a takeover proposal for Ashtead Technology, and compares the portfolio's valuation with the index.
In the second quarter of 2026 the partnership gained about 15.9%, against 15.2% for the S&P 500 Total Return Index. The letter introduces a new investment in Halozyme Therapeutics, with its risks, and closes the Goodfood chapter.
In the first quarter of 2026 the partnership declined by about 7.8%, against a 4.3% fall in the S&P 500 Total Return Index. The letter looks back on goeasy, an investment first made in 2019, and explains why volatile prices had created capital to deploy.
The partnership returned (4.2%) in the fourth quarter of 2025 and 34.0% for the full year, against 17.9% for the S&P 500 Total Return Index. The letter reviews the year's top contributors and detractors and the plans for Phoenician Intelligence in 2026.
In the third quarter of 2025 the partnership rose 11.6%, against 8.1% for the S&P 500 Total Return Index. We trimmed goeasy, Mader Group and Dino Polska after large gains and made two new investments, RS Technologies and Synektik.
In the second quarter of 2025 the partnership rose 21.1%, against 10.9% for the S&P 500 Total Return Index. The gains came from companies owned for years. The letter also sets out the Goodfood lesson, the ASA International board seat and the launch of Phoenician Intelligence.
In the first quarter of 2025 the partnership returned +3.4% while the S&P 500 Total Return fell 4.3%. The letter explains why the portfolio is resilient to trade tensions and introduces two new investments, Ashtead Technology and Auto Partner.